vs
EXACT SCIENCES CORP（EXAS）与礼恩派（LEG）财务数据对比。点击上方公司名可切换其他公司
礼恩派的季度营收约是EXACT SCIENCES CORP的1.1倍（$938.6M vs $878.4M），礼恩派净利率更高（2.7% vs -9.8%，领先12.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs -11.2%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $101.9M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -7.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
礼恩派（Leggett & Platt）总部位于美国密苏里州迦太基，是一家多元化制造企业，成立于1883年。公司专注于设计生产各类工程组件及产品，广泛应用于家居与汽车领域。目前旗下设有15个业务单元，在全球18个国家拥有135座生产工厂，员工总数达2万名。
EXAS vs LEG — 直观对比
营收规模更大
LEG
是对方的1.1倍
$878.4M
营收增速更快
EXAS
高出34.3%
-11.2%
净利率更高
LEG
高出12.5%
-9.8%
自由现金流更多
EXAS
多$18.5M
$101.9M
两年增速更快
EXAS
近两年复合增速
-7.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $938.6M |
| 净利润 | $-86.0M | $25.1M |
| 毛利率 | 70.1% | 17.9% |
| 营业利润率 | -9.4% | 2.0% |
| 净利率 | -9.8% | 2.7% |
| 营收同比 | 23.1% | -11.2% |
| 净利润同比 | 90.1% | 76.8% |
| 每股收益（稀释后） | $-0.45 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASLEG
| Q4 25 | $878.4M | $938.6M | ||
| Q3 25 | $850.7M | $1.0B | ||
| Q2 25 | $811.1M | $1.1B | ||
| Q1 25 | $706.8M | $1.0B | ||
| Q4 24 | $713.4M | $1.1B | ||
| Q3 24 | $708.7M | $1.1B | ||
| Q2 24 | $699.3M | $1.1B | ||
| Q1 24 | $637.5M | $1.1B |
净利润EXASLEG
| Q4 25 | $-86.0M | $25.1M | ||
| Q3 25 | $-19.6M | $127.1M | ||
| Q2 25 | $-1.2M | $52.5M | ||
| Q1 25 | $-101.2M | $30.6M | ||
| Q4 24 | $-864.6M | $14.2M | ||
| Q3 24 | $-38.2M | $44.9M | ||
| Q2 24 | $-15.8M | $-602.2M | ||
| Q1 24 | $-110.2M | $31.6M |
毛利率EXASLEG
| Q4 25 | 70.1% | 17.9% | ||
| Q3 25 | 68.6% | 18.7% | ||
| Q2 25 | 69.3% | 18.2% | ||
| Q1 25 | 70.8% | 18.6% | ||
| Q4 24 | 69.0% | 16.6% | ||
| Q3 24 | 69.4% | 18.2% | ||
| Q2 24 | 69.8% | 16.5% | ||
| Q1 24 | 70.0% | 17.0% |
营业利润率EXASLEG
| Q4 25 | -9.4% | 2.0% | ||
| Q3 25 | -3.0% | 14.9% | ||
| Q2 25 | -0.3% | 6.8% | ||
| Q1 25 | -13.6% | 4.4% | ||
| Q4 24 | -122.8% | 2.4% | ||
| Q3 24 | -5.6% | 5.2% | ||
| Q2 24 | -3.8% | -56.2% | ||
| Q1 24 | -16.7% | 3.9% |
净利率EXASLEG
| Q4 25 | -9.8% | 2.7% | ||
| Q3 25 | -2.3% | 12.3% | ||
| Q2 25 | -0.1% | 5.0% | ||
| Q1 25 | -14.3% | 3.0% | ||
| Q4 24 | -121.2% | 1.3% | ||
| Q3 24 | -5.4% | 4.1% | ||
| Q2 24 | -2.3% | -53.4% | ||
| Q1 24 | -17.3% | 2.9% |
每股收益（稀释后）EXASLEG
| Q4 25 | $-0.45 | $0.18 | ||
| Q3 25 | $-0.10 | $0.91 | ||
| Q2 25 | $-0.01 | $0.38 | ||
| Q1 25 | $-0.54 | $0.22 | ||
| Q4 24 | $-4.69 | $0.10 | ||
| Q3 24 | $-0.21 | $0.33 | ||
| Q2 24 | $-0.09 | $-4.39 | ||
| Q1 24 | $-0.60 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $587.4M |
| 总债务越低越好 | — | $1.5B |
| 股东权益账面价值 | $2.4B | $1.0B |
| 总资产 | $5.9B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 1.46× |
8季度趋势，按日历期对齐
现金及短期投资EXASLEG
| Q4 25 | $964.7M | $587.4M | ||
| Q3 25 | $1.0B | $460.7M | ||
| Q2 25 | $858.4M | $368.8M | ||
| Q1 25 | $786.2M | $412.6M | ||
| Q4 24 | $1.0B | $350.2M | ||
| Q3 24 | $1.0B | $277.2M | ||
| Q2 24 | $946.8M | $307.0M | ||
| Q1 24 | $652.1M | $361.3M |
总债务EXASLEG
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益EXASLEG
| Q4 25 | $2.4B | $1.0B | ||
| Q3 25 | $2.5B | $971.8M | ||
| Q2 25 | $2.5B | $855.0M | ||
| Q1 25 | $2.4B | $746.8M | ||
| Q4 24 | $2.4B | $689.4M | ||
| Q3 24 | $3.2B | $741.0M | ||
| Q2 24 | $3.2B | $667.6M | ||
| Q1 24 | $3.1B | $1.3B |
总资产EXASLEG
| Q4 25 | $5.9B | $3.5B | ||
| Q3 25 | $5.9B | $3.5B | ||
| Q2 25 | $5.8B | $3.7B | ||
| Q1 25 | $5.7B | $3.7B | ||
| Q4 24 | $5.9B | $3.7B | ||
| Q3 24 | $6.7B | $3.8B | ||
| Q2 24 | $6.7B | $3.8B | ||
| Q1 24 | $6.4B | $4.6B |
负债/权益比EXASLEG
| Q4 25 | — | 1.46× | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 2.10× | ||
| Q1 25 | — | 2.59× | ||
| Q4 24 | — | 2.70× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 2.55× | ||
| Q1 24 | — | 1.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $121.5M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $101.9M |
| 自由现金流率自由现金流/营收 | 13.7% | 10.9% |
| 资本支出强度资本支出/营收 | 3.6% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 4.84× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $281.0M |
8季度趋势，按日历期对齐
经营现金流EXASLEG
| Q4 25 | $151.7M | $121.5M | ||
| Q3 25 | $219.9M | $125.9M | ||
| Q2 25 | $89.0M | $84.0M | ||
| Q1 25 | $30.8M | $6.8M | ||
| Q4 24 | $47.1M | $122.3M | ||
| Q3 24 | $138.7M | $95.5M | ||
| Q2 24 | $107.1M | $94.0M | ||
| Q1 24 | $-82.3M | $-6.1M |
自由现金流EXASLEG
| Q4 25 | $120.4M | $101.9M | ||
| Q3 25 | $190.0M | $110.1M | ||
| Q2 25 | $46.7M | $75.5M | ||
| Q1 25 | $-365.0K | $-6.5M | ||
| Q4 24 | $10.7M | $100.5M | ||
| Q3 24 | $112.6M | $77.1M | ||
| Q2 24 | $71.2M | $78.5M | ||
| Q1 24 | $-120.0M | $-32.0M |
自由现金流率EXASLEG
| Q4 25 | 13.7% | 10.9% | ||
| Q3 25 | 22.3% | 10.6% | ||
| Q2 25 | 5.8% | 7.1% | ||
| Q1 25 | -0.1% | -0.6% | ||
| Q4 24 | 1.5% | 9.5% | ||
| Q3 24 | 15.9% | 7.0% | ||
| Q2 24 | 10.2% | 7.0% | ||
| Q1 24 | -18.8% | -2.9% |
资本支出强度EXASLEG
| Q4 25 | 3.6% | 2.1% | ||
| Q3 25 | 3.5% | 1.5% | ||
| Q2 25 | 5.2% | 0.8% | ||
| Q1 25 | 4.4% | 1.3% | ||
| Q4 24 | 5.1% | 2.1% | ||
| Q3 24 | 3.7% | 1.7% | ||
| Q2 24 | 5.1% | 1.4% | ||
| Q1 24 | 5.9% | 2.4% |
现金转化率EXASLEG
| Q4 25 | — | 4.84× | ||
| Q3 25 | — | 0.99× | ||
| Q2 25 | — | 1.60× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 8.61× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
LEG
| Bedding Products | $373.8M | 40% |
| Flooring And Textile Products Group | $196.9M | 21% |
| Automotive Group | $194.9M | 21% |
| Work Furniture Group | $66.2M | 7% |
| Home Furniture Group | $61.0M | 6% |
| Hydraulic Cylinders | $45.8M | 5% |
